NYSE:LHHealthcare
Will Analyst Upgrades and ColoSense Momentum Change Labcorp Holdings' (LH) Narrative
In recent weeks, Labcorp Holdings has drawn attention as analysts raised earnings estimates ahead of its June 2026 quarter results, with consensus pointing to year-over-year growth in both revenue and profit and continued momentum from new offerings like its FDA-approved at-home ColoSense colorectal cancer screening test with expanded Medicare coverage.
This shift in expectations, alongside Labcorp’s record of topping forecasts in the last four quarters, highlights how product innovation and...